BUFFALO, NEW YORK (PRWEB) JULY 19, 2017
MMJ International Holdings, the premier medical cannabis research company that is advancing the science of medical marijuana through patient clinical research and operation of medical cannabis healthcare businesses, today announced that its affiliate MMJ Bioscience, is developing the first pharmaceutical formulation of cannabidiol (CBD) derived from certain extracts of the cannabis plant. MMJ BioScience is also currently beginning Phase 2 studies with a new drug for the treatment of primary progressive multiple sclerosis.
